company background image
MRVI

Maravai LifeSciences Holdings NasdaqGS:MRVI Stock Report

Last Price

US$27.88

Market Cap

US$7.1b

7D

4.7%

1Y

-34.8%

Updated

28 Jun, 2022

Data

Company Financials +
MRVI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance6/6
Financial Health4/6
Dividends0/6

MRVI Stock Overview

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.

Maravai LifeSciences Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Maravai LifeSciences Holdings
Historical stock prices
Current Share PriceUS$27.88
52 Week HighUS$63.55
52 Week LowUS$23.16
Beta0
1 Month Change-18.67%
3 Month Change-21.75%
1 Year Change-34.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-6.60%

Recent News & Updates

Jun 27
Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

In this article we are going to estimate the intrinsic value of Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI ) by...

Shareholder Returns

MRVIUS Life SciencesUS Market
7D4.7%4.5%1.7%
1Y-34.8%-19.0%-20.4%

Return vs Industry: MRVI underperformed the US Life Sciences industry which returned -17.4% over the past year.

Return vs Market: MRVI underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is MRVI's price volatile compared to industry and market?
MRVI volatility
MRVI Average Weekly Movement9.4%
Life Sciences Industry Average Movement11.3%
Market Average Movement8.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: MRVI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MRVI's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2020520Carl Hullhttps://www.maravai.com

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.

Maravai LifeSciences Holdings Fundamentals Summary

How do Maravai LifeSciences Holdings's earnings and revenue compare to its market cap?
MRVI fundamental statistics
Market CapUS$7.14b
Earnings (TTM)US$225.80m
Revenue (TTM)US$895.32m

16.2x

P/E Ratio

4.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRVI income statement (TTM)
RevenueUS$895.32m
Cost of RevenueUS$149.20m
Gross ProfitUS$746.12m
Other ExpensesUS$520.32m
EarningsUS$225.80m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.72
Gross Margin83.34%
Net Profit Margin25.22%
Debt/Equity Ratio81.0%

How did MRVI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MRVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRVI?

Other financial metrics that can be useful for relative valuation.

MRVI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.6x
Enterprise Value/EBITDA6.3x
PEG Ratio7.2x

Price to Earnings Ratio vs Peers

How does MRVI's PE Ratio compare to its peers?

MRVI PE Ratio vs Peers
The above table shows the PE ratio for MRVI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average42.2x
SYNH Syneos Health
30.3x19.8%US$7.3b
SHC Sotera Health
42.5x25.9%US$5.8b
RGEN Repligen
62.9x19.3%US$9.1b
BRKR Bruker
33.1x14.9%US$9.5b
MRVI Maravai LifeSciences Holdings
16.2x2.3%US$7.1b

Price-To-Earnings vs Peers: MRVI is good value based on its Price-To-Earnings Ratio (16.2x) compared to the peer average (42.2x).


Price to Earnings Ratio vs Industry

How does MRVI's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: MRVI is good value based on its Price-To-Earnings Ratio (16.2x) compared to the US Life Sciences industry average (30.9x)


Price to Earnings Ratio vs Fair Ratio

What is MRVI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRVI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.2x
Fair PE Ratio24.6x

Price-To-Earnings vs Fair Ratio: MRVI is good value based on its Price-To-Earnings Ratio (16.2x) compared to the estimated Fair Price-To-Earnings Ratio (24.6x).


Share Price vs Fair Value

What is the Fair Price of MRVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MRVI ($27.88) is trading above our estimate of fair value ($23.95)

Significantly Below Fair Value: MRVI is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: MRVI is poor value based on its PEG Ratio (7.2x)


Discover undervalued companies

Future Growth

How is Maravai LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRVI's forecast earnings growth (2.3% per year) is above the savings rate (1.9%).

Earnings vs Market: MRVI's earnings (2.3% per year) are forecast to grow slower than the US market (13.8% per year).

High Growth Earnings: MRVI's earnings are forecast to grow, but not significantly.

Revenue vs Market: MRVI's revenue is expected to decline over the next 3 years (-6.8% per year).

High Growth Revenue: MRVI's revenue is forecast to decline over the next 3 years (-6.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRVI's Return on Equity is forecast to be high in 3 years time (26.5%)


Discover growth companies

Past Performance

How has Maravai LifeSciences Holdings performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


69.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MRVI has high quality earnings.

Growing Profit Margin: MRVI's current net profit margins (25.2%) are higher than last year (20.4%).


Past Earnings Growth Analysis

Earnings Trend: MRVI's earnings have grown significantly by 69.3% per year over the past 5 years.

Accelerating Growth: MRVI's earnings growth over the past year (190.7%) exceeds its 5-year average (69.3% per year).

Earnings vs Industry: MRVI earnings growth over the past year (190.7%) exceeded the Life Sciences industry 21%.


Return on Equity

High ROE: MRVI's Return on Equity (82.6%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Maravai LifeSciences Holdings's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MRVI's short term assets ($619.1M) exceed its short term liabilities ($86.7M).

Long Term Liabilities: MRVI's short term assets ($619.1M) do not cover its long term liabilities ($1.3B).


Debt to Equity History and Analysis

Debt Level: MRVI's net debt to equity ratio (15%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MRVI's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MRVI's debt is well covered by operating cash flow (92.9%).

Interest Coverage: MRVI's interest payments on its debt are well covered by EBIT (25.1x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Maravai LifeSciences Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MRVI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MRVI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MRVI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MRVI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MRVI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Carl Hull (62 yo)

8.25yrs

Tenure

US$1,780,769

Compensation

Mr. Carl W. Hull serves as a Director of Ortho-Clinical Diagnostics, Inc. Mr. Hull serves as an Independent Director at Ortho Clinical Diagnostics Holdings plc since 2021. Mr. Hull Co-Founder, Chief Execut...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD1.78M) is below average for companies of similar size in the US market ($USD8.23M).

Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MRVI's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: MRVI's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Maravai LifeSciences Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Maravai LifeSciences Holdings, Inc.
  • Ticker: MRVI
  • Exchange: NasdaqGS
  • Founded: 2020
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$7.139b
  • Market Cap: US$3.667b
  • Shares outstanding: 255.21m
  • Website: https://www.maravai.com

Number of Employees


Location

  • Maravai LifeSciences Holdings, Inc.
  • 10770 Wateridge Circle
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.